Register for your FREE account now and join thousands of oncology professionals who stay informed about patient care issues, practical oncology-care management techniques, and drug administration and dosage information.

Keep me logged in Forgot your password?

Please wait...

Please wait...

Vemurafenib (Zelboraf)

, Maribel Pereiras, PharmD, BCPS, BCOP May 11, 2012

Vemurafenib is a B-RAF enzyme inhibitor indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation.
 

Cabazitaxel (Jevtana)

April 17, 2012

Cabazitaxel is a taxane derivative indicated for treatment of hormone-refractory metastatic prostate cancer in patients previously treated with a docetaxel-containing regimen.
 

Asparaginase Erwinia chrysanthemi (Erwinaze)

February 22, 2012

Asparaginase Erwinia chrysanthemi is a component of a multiagent regimen for treatment of acute lymphoblastic leukemia.
 

Brentuximab vedotin (Adcetris)

December 19, 2011

An antibody-drug conjugate indicated for the treatment of Hodgkin lymphoma and sALCL after failure of prior multiagent regimens.
 

Methylnaltrexone (Relistor)

October 19, 2011

Methylnaltrexone is a peripheral acting narcotic antagonist, opioid reversing agent. It is indicated for treatment of opioid-induced constipation.
 

Ipilimumab (Yervoy)

August 01, 2011

Ipilimumab is a recombinant, human cytotoxic T-lymphocyte antigen 4-blocking monoclonal antibody indicated for the treatment of unresectable or metastatic melanoma.
 

Oxaliplatin (Eloxatin)

April 18, 2011

Oxaliplatin is a platinum-containing antineoplastic agent used to treat lymph node positive colorectal carcinoma and metastatic colorectal cancer.
 

Fluorouracil IV (5-FU, Adrucil)

March 17, 2011

Fluorouracil is an antimetabolite antineoplastic agent indicated for colorectal, gastric, metastatic breast, metastatic colorectal, and pancreatic cancers.
 

Cisplatin (Platinol, Platinol-AQ)

February 01, 2011

Cisplatin is a platinum-containing, aklylating agent. It is often used in combination with other chemotherapy agents as well as monotherapy because of its relative lack of hematologic toxicity.
 

Erlotinib (Tarceva)

October 26, 2010

Erlotinib is a human epidermal growth factor receptor type 1/epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor approved for non-small cell lung cancer and pancreatic cancer.
 

Zoledronic acid (zoledronate, Zometa)

September 01, 2010

Zoledronic acid is a third-generation bisphosphonate prescribed to reduce pain from bony metastases, treat hypercalcemia of malignancy, and manage osteolytic lesions in multiple myeloma.
 

Doxorubicin

August 01, 2010

Doxorubicin is an anthracycline antibiotic that is used to treat lymphoblastic and acute myeloblastic leukemias, several types of cancer, Kaposi sarcoma related to AIDS, malignant lymphoma, soft tissue and osteogenic sarcomas, and Wilms tumor.
 

Tamoxifen

July 15, 2010

Stat Consult provides rapid reviews of important drugs used in oncology. This month's column reviews the use of tamoxifen for treatment and prevention of breast cancer.
 

Arsenic trioxide (Trisenox)

June 15, 2010

Stat Consult provides rapid reviews of important drugs used in oncology.
 

Trastuzumab (Herceptin)

May 01, 2010

Stat Consult provides rapid reviews of important drugs used in oncology.
 

Web Exclusives

BI-RADS and breast MRI useful in predicting malignancy

Delicia Honen Yard May 30, 2012

The Breast Imaging Reporting and Data System (BI-RADS) terminology is useful in predicting malignancy in breast lesions detected with MRI.
 

Posttransplant lenalidomide can slow down multiple myeloma

Delicia Honen Yard May 29, 2012

Lenalidomide use after autologous stem-cell transplant significantly improved progression-free and overall survival in patients with myeloma.
 

Melanoma genome study implicates sun and new genetic culprits

Delicia Honen Yard May 28, 2012

Genetic mutations increased along with chronic sun exposure in persons with melanoma, and yet another gene may contribute to disease risk as well.
 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions